Guobang Pharma Ltd.
SSE:605507.SS
20.53 (CNY) • At close June 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 5,890.839 | 5,349.448 | 5,720.925 | 4,505.351 | 4,206.318 | 3,802.036 | 3,279.017 | 2,905.475 |
| Cost of Revenue
| 4,418.113 | 4,140.599 | 4,144.882 | 3,147.622 | 2,755.453 | 2,815.839 | 2,304.328 | 2,064.465 |
| Gross Profit
| 1,472.727 | 1,208.849 | 1,576.043 | 1,357.729 | 1,450.865 | 986.198 | 974.69 | 841.01 |
| Gross Profit Ratio
| 0.25 | 0.226 | 0.275 | 0.301 | 0.345 | 0.259 | 0.297 | 0.289 |
| Reseach & Development Expenses
| 215.052 | 191.993 | 197.542 | 155.272 | 137.187 | 124.344 | 103.297 | 94.727 |
| General & Administrative Expenses
| 89.73 | 107.432 | 91.502 | 91.569 | 60.19 | 53.144 | 45.09 | 139.592 |
| Selling & Marketing Expenses
| 45.445 | 46.675 | 64.154 | 55.865 | 74.886 | 76.663 | 70.762 | 61.491 |
| SG&A
| 135.175 | 358.079 | 155.656 | 147.434 | 135.076 | 129.806 | 115.852 | 201.084 |
| Other Expenses
| 227.432 | -43.487 | 221.864 | 176.279 | 148.594 | 140.426 | -17.863 | -16.429 |
| Operating Expenses
| 577.659 | 506.585 | 575.063 | 478.984 | 420.856 | 394.576 | 353.76 | 313.767 |
| Operating Income
| 895.067 | 702.263 | 1,052.878 | 808.774 | 936.116 | 581.587 | 579.69 | 469.328 |
| Operating Income Ratio
| 0.152 | 0.131 | 0.184 | 0.18 | 0.223 | 0.153 | 0.177 | 0.162 |
| Total Other Income Expenses Net
| -7.098 | -4.615 | -17.238 | -1.993 | 7.321 | -5.664 | -17.863 | -16.429 |
| Income Before Tax
| 887.97 | 697.649 | 1,035.639 | 806.782 | 943.437 | 575.923 | 561.827 | 452.899 |
| Income Before Tax Ratio
| 0.151 | 0.13 | 0.181 | 0.179 | 0.224 | 0.151 | 0.171 | 0.156 |
| Income Tax Expense
| 107.392 | 87.67 | 115.017 | 100.552 | 133.149 | 81.915 | 78.37 | 61.654 |
| Net Income
| 781.595 | 612.464 | 920.904 | 706.03 | 810 | 494.008 | 210.872 | 177.73 |
| Net Income Ratio
| 0.133 | 0.114 | 0.161 | 0.157 | 0.193 | 0.13 | 0.064 | 0.061 |
| EPS
| 1.4 | 1.1 | 1.65 | 1.26 | 1.45 | 0.88 | 0.44 | 0.37 |
| EPS Diluted
| 1.4 | 1.1 | 1.65 | 1.26 | 1.45 | 0.88 | 0.44 | 0.37 |
| EBITDA
| 1,348.629 | 1,047.504 | 1,312.473 | 1,042.604 | 1,136.071 | 748.696 | 728.046 | 601.961 |
| EBITDA Ratio
| 0.229 | 0.196 | 0.229 | 0.231 | 0.27 | 0.197 | 0.222 | 0.207 |